Recent Press Releases

Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia

PR Newswire Seattle Children's 1 hour ago  SEATTLE, April 21, 2015 /PRNewswire/ -- Seattle Children's announced today that 20 of 22 patients treated thus far in a clinical trial using...

Dimension Therapeutics Secures $65 Million in Oversubscribed Series B Financing

Dimension Is Advancing Liver-Directed Gene Therapy Treatments for Rare Metabolic Disorders and Hemophilia Based on Innovative AAV Technologies and a Proprietary Manufacturing Platform April 21, 2015...

Alnylam Reports 12-Month Clinical Data from Phase 2 Open Label Extension (OLE) Study of Patisiran, an Investigational RNAi Therapeutic for Patients with Familial Amyloidotic Polyneuropathy (FAP)

– A Mean 2.5 Point Decrease in mNIS+7 Endpoint Compares Favorably to 13 to 18 Point Increase Estimated from Analysis of Historical Data Sets, and is Consistent with Therapeutic Hypothesis that...

Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia Tuesday, April 21, 2015 - 8:00am Pfizer today...

Global Strategic Partners Merck and Pfizer Initiate Phase III Study with Avelumab in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer

First of several registration trials expected to start in 2015 for the alliance between Merck and Pfizer Initiation and first patient treated in Phase III clinical study recruiting across...

TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors

MALVERN, Pa. & KENILWORTH, N.J.--TetraLogic Pharmaceuticals Corporation (Nasdaq: TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule...

Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a supplemental Biologics License Application to...

Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA® (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine

Data Formed the Basis for KEYTRUDA U.S. FDA Submission and Breakthrough Therapy Designation in Advanced NSCLC PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States...

Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis

INDIANAPOLIS, April 20, 2015 -- Eli Lilly and Company (NYSE: LLY) announced today that the investigational medicine ixekizumab was statistically superior to placebo in the treatment of patients with...

CART-meso immunotherapy feasible for patients with advanced cancers

Patients with advanced cancers who received chimeric antigen receptor- modified T cells (CART)-meso, a type of adoptive immunotherapy, tolerated the treatment well, and there was evidence that the...

Curadev Announces Research Collaboration and Licensing Agreement to Develop Cancer Immunotherapeutic

NEW DELHI, India, April 20, 2015 -- Curadev Pharma Private Ltd. today announced that it has entered into a research collaboration and exclusive license agreement with Roche for the development and...

CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research

KYOTO and OSAKA, Japan -- Center for iPS Cell Research Application (CiRA) of Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) announced today that they will work together to...

Vaxin, Inc. Names Elizabeth Adkins Czerepak As Chief Financial Officer

GAITHERSBURG, MD--(Marketwired - April 13, 2015) - Today, Vaxin strengthened its leadership team by appointing Elizabeth Adkins Czerepak to the newly created position of chief financial officer...

Blend Therapeutics Appoints Drew Fromkin As President And Chief Executive Officer

WATERTOWN, Mass.--(BUSINESS WIRE)--Blend Therapeutics, Inc., a biopharmaceutical company discovering and developing two distinct classes of targeted anti-cancer medicines to advance the treatment of...

Zoetis Appoints Paul M. Bisaro to Board of Directors

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that its Board of Directors has appointed Paul M. Bisaro, Executive Chairman of Actavis plc, to the company's Board of...

MPM Capital Appoints Gregory Sieczkiewicz as Managing Director and Chief Counsel – Intellectual Property

-Experienced VC patent expert to provide IP counsel- BOSTON--(BUSINESS WIRE)--MPM Capital today announces the appointment of Gregory Sieczkiewicz as Managing Director and Chief Counsel, Intellectual...

CAPNIA, Inc. Appoints Edward Ebbers As Chief Commercial Officer

REDWOOD CITY, Calif., April 13, 2015 (GLOBE NEWSWIRE) -- Capnia, Inc. (Nasdaq:CAPN), focused on the development of novel products based on its proprietary technologies for precision metering of gas...

Phlexglobal Announces Rick Riegel as Chief Executive Officer

AMERSHAM, England & MALVERN, Pa.--(BUSINESS WIRE)--Phlexglobal, the specialist provider of innovative Trial Master File (TMF) and electronic Trial Master File (eTMF) expertise, solutions and...

Halozyme Therapeutics, Inc. (HALO) Appoints Harry J. Leonhardt, Esq. As Senior Vice President, General Counsel And Chief Compliance Officer

SAN DIEGO, April 13, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of...

Egalet Appoints Nicholas Nicolaides, Ph.D. And John Osborn To Board of Directors

WAYNE, Pa., April 13, 2015 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and...